Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 62 results for neuropathic pain

  1. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NG193)

    This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.

  2. Cannabis-based medicinal products (NG144)

    This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

  3. Pancreatitis (NG104)

    This guideline covers managing acute and chronic pancreatitis in children, young people and adults. It aims to improve quality of life by ensuring that people have the right treatment and follow-up, and get timely information and support after diagnosis.

  4. Low back pain and sciatica in over 16s: assessment and management (NG59)

    This guideline covers assessing and managing low back pain and sciatica in people aged 16 and over. It outlines physical, psychological, pharmacological and surgical treatments to help people manage their low back pain and sciatica in their daily life. The guideline aims to improve people’s quality of life by promoting the most effective forms of care for low back pain and sciatica.

  5. Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain (MIB238)

    NICE has developed a medtech innovation briefing (MIB) on Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain .

  6. Medicines Optimisation for Neuropathic Pain

    the team sought to improve quality and efficiency of prescribing for neuropathic pain, whilst reducing variation in prescribing...

  7. What are the key factors, including additional care and support, that influence participation* and quality of life in people with neuropathic pain?

    support, that influence participation* and quality of life in people with neuropathic pain? Any explanatory notes(if applicable) * The...

  8. Does early intervention to treat neuropathic pain reduce the likelihood of chronic pain?

    Question Does early intervention to treat neuropathic pain reduce the likelihood of chronic pain? Any explanatory notes(if...

  9. What is the clinical effectiveness, cost effectiveness and tolerability of pharmacological monotherapy compared with combination therapy for treating neuropathic pain?

    pharmacological monotherapy compared with combination therapy for treating neuropathic pain? Any explanatory notes(if applicable) Why...

  10. Is there a potential for dependence associated with pharmacological agents for neuropathic pain?

    potential for dependence associated with pharmacological agents for neuropathic pain? Any explanatory notes(if applicable) There has...

  11. Is response to pharmacological treatment predicted more reliably by underlying aetiology or by symptom characteristics?

    symptoms that present in healthcare settings, or whether different neuropathic pain conditions with different aetiologies, respond...

  12. What is the clinical and cost effectiveness of carbamazepine as initial treatment for trigeminal neuralgia compared with other pharmacological treatments?

    efficacious. Source guidance details Comes from guidance Neuropathic pain in adults: pharmacological management in non-specialist...

  13. How should the symptomatic treatment of neuropathic pain relate to its cause?

    CG173/7 Question How should the symptomatic treatment of neuropathic pain relate to its cause? Any explanatory notes(if applicable)

  14. What is the clinical and cost effectiveness of alternative treatments as firstline treatment for trigeminal neuralgia compared with other better-tolerated pharmacological treatments?

    applicable) Source guidance details Comes from guidance Neuropathic pain in adults: pharmacological management in non-specialist...

  15. What is the clinical and cost effectiveness of lidocaine patches for localised peripheral pain?

    peripheral pain? Any explanatory notes(if applicable) Source guidance details Comes from guidance Neuropathic pain in...